• Established as a Delaware Corp in February 2014!
• 4 full time employees and 6 part time!
• Lab in Heidelberg at the EMBL!
• Office in Mexico city for hardware and software
design and development!
• Business development and R&D team moving to
the SF Bay Area from January 2015
We radically improve the ability of Life Science Research
and Healthcare providers to diagnose, treat and monitor
disease at the molecular level through the examination of
• Start – to – finish platform!
• Accurate !
• Increased reproducibility!
• Low cost of equipment and assays!
• Simplified prep and device operation:
No need of special training!
• Custom content!
• Centralized analytics platform for
results that allows stratification and
correlate data with other contextual
1. We are able to detect 5 circulating microRNAs from human
samples with our method!
2. Collaboration agreement with the European Molecular Biology
Lab (EMBL) and DKFZ in Germany and National Institute of
Genomic Medicine (INMEGEN) in Mexico for sample collection,
clinical trials and assay optimization!
3. Working prototype of the bioassay, the device and the analytics
What We Do
Miroculus brings an accurate, easy to use, non-invasive, operator independent and affordable
microRNA detection platform for molecular data gathering, analysis and interpretation
Other Company Facts
MicroRNAs are small molecules that
regulate gene expression. Unlike DNA,
which is mainly fixed, microRNAs can
vary depending on both internal and
environmental conditions, telling us which
genes are actively expressed at any given
MicroRNAs play an important role in the
regulation of protein production, and
hence, the onset and progression of many
diseases, particularly cancer and
What are microRNAS?
Before a protein is expressed, or produced,
relevant parts of its genetic code present in
the DNA are copied into the messenger
RNA. This messenger RNA has the
instructions on how to build a specific
protein. It can potentially build multiple
protein molecules, but the actual output is
regulated or modulated by microRNAs.
Number of peer-reviewed scientific !
publications of miRNA-related discoveries.
Mandhavan et al 2013
" Monitor asymptomatic high-risk individuals.!
" Identification of early-stage cancer.!
" Discrimination between benign and malignant
" Predict disease outcome.!
" Predict progression-free and overall survival.!
" Monitor disease recurrence.
" Monitor sensitivity to therapy and therapy
" Aid treatment decisions.!
" Existing molecular diagnostic test based on microRNA FDA approved and
" Many more in clinical trials and regulatory process (US, EU, Asia)!
" Reimbursements approved in the US!
" The Japanese National Cancer Center (NCC) and the National Center for
Geriatrics and Gerontology (NCGG) launched a project to develop a next-
generation diagnosis system based on microRNA that enables to detect 13
types of cancers including breast and large bowel cancers with a blood
Existing microRNA profiling techniques requires
expensive lab machinery, specially trained
technicians, centralized lab facilities and slow
results turnaround times.
Complex diseases require parallel analysis of molecular events across the gene, protein
and cell in order to monitor resistance, progression, recurrence and response
How are we solving it?
We are radically improving how procedures and diagnostics are being done, !
with an accurate, easy to use, non-invasive, operator independent and affordable microRNA
Our microRNA detection platform provides
quantitative and qualitative molecular level
monitoring before, during and after therapy for
carcinogenesis and metabolic diseases. The
entire platform costs at least 50 times less than
current microRNA profiling methods making
microRNA detection simpler and more
affordable than ever before.
We’ve designed and developed a
microRNA platform with 3 products: an
accurate molecular bioassay to detect
microRNAs from plasma, a low cost device
to run the reaction and data mining and
A bioassay, which in presence of microRNA, !
generates signal visible with naked eye
Sensitivity down to 1 attomole observed with mir-122 and let-7a
Our first working prototype uses your smartphone to processes the results, and by the end of 2014
we will have available a new version that will process the results by itself.!
Wells that shine are matched with specific microRNAs, and analyzed in terms of how much
and how fast they shine. This tells us which microRNAs are present in the sample and
whether they are over-regulated or down-regulated.
The architecture of the device uses existing low-cost electronic components
The gathering and mining of data in the cloud allows our customers to get results !
in real time and perform analytics with other contextual information. This will let !
us better understand and decode diseases.
Our HIPAA compliant platform allows you to stratify patients, visualize trends,
add events and find correlations
Who are our potential customers?
This is how we estimate our market
Our Primary Market: Life Sciences
Pharma & Biotech
Academia, Gov. Labs, Genomic Research Centers
Our Secondary Market: Health Providers IVD
As new findings and more tests results are aggregated,
the opportunity to personalize trials, create scenarios
and find correlations and causations with our data will
be our fastest growing product
We will sell our multi-microRNA screening assay
with Miroculus’ biochemistry
Plates with Bioassay
Through strategic partnerships, we will manufacture and
distribute our device with an outsourced and low cost
strategy, facilitating the adoption from our customers
while disrupting the market
Annual license to access our analytics platform
Recurrent sales of customized and standard plates with bioassay & customized
data driven analysis and data mining
Plates with bioassay
License fee of the analytics platform
Alejandro Tocigl Domeyko. !
Chief Executive Officer!
Alejandro is an experienced
entrepreneur who sits on the board
of different early stage ventures.
He has created and financially
structured two companies;
managed to turn around and sell
four companies and has invested
in 39 early stage ventures.
Foteini Christodoulou. PhD!
Chief Scientific Officer!
Fay is a Postdoc studying microRNAs in
cancer. She completed her PhD in
Molecular Biology at the European
Molecular Biology Laboratory and gives
lectures at the European Molecular
Biology Organization. Her work with
microRNAs has been published in
Nature and Cell Magazine.
Jorge Soto. !
Chief Product & Technology
Jorge is an Electronics Engineer
and former Deputy General
Director of Civic Innovation at the
Office of the President of Mexico.
He is an Endeavor Entrepreneur,
World Economic Forum
Technology Pioneer and MIT TR35.
Katarina Cuk, PhD !
Katarina has a PhD from the
German Cancer Research Center
(DKFZ) in Heidelberg. She has
been working with circulating
microRNAs as potential biomarkers
for the early detection of breast
cancer for the last four years.
Juho Terrijarvi, MS!
Director of Engineering!
Juho holds a Master of Science in
Technology from Turku University. Aside
from giving lectures on Engineering, he
has been working on IVD measurement
device platforms including both hardware
Artemis Hatzigeorgiou. PhD!
Director of Bioinformatics!
Artemis is Professor of Bioinformartics
at the Department of Electrical &
Computer Engineering at the
University of Thessaly. She developed
DIANA-microT, one of the first
published microRNA target prediction
program. She is a recipient of the NSF
Young Investigator Award.
Miroculus Agilent Exiqon Illumina Qiagen Rosetta
Assay Miroculus assay SurePrint G3
Human Serum &
miRNA PCR Array
N/A Firefly microRNA
Price of Assay
200 15.193 16.138 900 19.468 5.000 9.167
Time to results 90 minutes 2 days 2 days 2 days 2 days 7 days 10 days
Miriam: low cost
open source device
(ABI 7900 HT or
(ABI 7900 HT or
N/A as it is a
Price of Device
400 129.495 16.900 for
for ABI 7900 HT
95.000 16.900 for
for ABI 7900 HT
N/A as it is a
NO YES YES YES YES YES YES
Scope Multi purpose:
Research Research Research Research Molecular
● Firefly Bioworks provides only a centralized microRNA profiling service where samples need to be sent under special conditions to a Lab.!
● Rosetta Genomics is the sole provider of microRNA based diagnostics but as a centralized service where samples need to be sent under special
conditions to a Lab in the US.